Testing a new medication for hallucinations and delusions in Alzheimer's disease

Plain-English translation of NCT06887192 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This is a Phase 2 research study testing whether a medication called can help reduce hallucinations (seeing or hearing things that aren't there) and delusions (strong false beliefs) in people who have Alzheimer's disease. Half of the participants will receive the new medication, and half will receive a placebo (an inactive pill that looks identical) so researchers can compare how well it works. The study will track changes in these symptoms over time to see if the medication is safe and effective.

Hallucinations and delusions are distressing symptoms that occur in some people with advanced Alzheimer's disease, but current treatment options are limited. This medication is being tested to see if it can safely reduce these symptoms and improve quality of life for patients and their caregivers.

Do you qualify?

You likely qualify if…

you are between 55 and 90 years old
you have been diagnosed with possible or probable Alzheimer's disease
you have experienced hallucinations or delusions for at least 2 months
you have lived in the same home, assisted living, or nursing facility for at least 6 weeks
you have a family member or care partner who can help track your symptoms and medication use
your hallucinations and delusions are moderate to severe, as measured by standard clinical assessments

You likely don't qualify if…

you are receiving hospice care or end-of-life palliative care
your psychotic symptoms are caused primarily by substance use or another medical condition (not Alzheimer's disease)
you have a serious brain disorder other than Alzheimer's disease affecting your thinking
you have had severe depression in the past 3 months or have thoughts of harming yourself
you have a history of alcohol or substance abuse in the past year

What participation looks like

If you join this study, you will be randomly assigned to either receive the new medication or a placebo pill. You and the research team will not know which one you're getting (this is called 'double-blind'). You will need to visit the clinic regularly so doctors can check how you're doing, measure any changes in your symptoms, and monitor your safety. Your care partner will also be asked to help report on your symptoms and medication adherence throughout the study.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(52 sites)

United States

Clinical Site, Phoenix, Arizona

Clinical Site, Scottsdale, Arizona

Clinical Site, Tucson, Arizona

Clinical Site, Anaheim, California

Clinical Site, Murrieta, California